Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 1

Альтернативные подходы к коррекции гиперхолестеринемии: эффекты стандартизированных экстрактов красного риса и его синергистов
И.Ю. Торшин, О.А. Громова

Список литературы

1. Кухарчук ВВ. О новой версии рекомендаций по коррекции дислипидемии с целью профилактики атеросклероза и его осложнений. Атеросклероз и дислипидемии 2020;1(38):5-6.
2. Global Burden of Cardiovascular Diseases Collaboration; Roth GA, Johnson CO, Abate KH, Abd-Allah F, Ahmed M, Alam K, Alam T, Alvis-Guzman N, Ansari H, Ärnlöv J, Atey TM, Awasthi A, Awoke T, Barac A, Bärnighausen T, Bedi N, Bennett D, Bensenor I, Biadgilign S, Castañeda-Orjuela C, Catalá-López F, Davletov K, Dharmaratne S, Ding EL, Dubey M, Aquino Faraon EJ, Farid T, Farvid MS, Feigin V, Fernandes J, Frostad J, Gebru A, Geleijnse JM, Nyakauru Gona PN, Griswold M, Hailu GB, Hankey GJ, Hassen HY, Havmoeller R, Hay S, Heckbert SR, Irvine CMS, James SL, Jara D, Kasaeian A, Khan AR, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Lal D, Larsson A, Linn S, Lotufo PA, Abd El Razek NM, Mazidi M, Meier T, Mendoza W, Mensah GA, Meretoja A, Mezgebe HB, Mirrakhimov E, Mohammed S, Moran AE, Nguyen G, Nguyen M, Ong KL, Owolabi M, Pletcher M, Pourmalek F, Purcell CA, Qorbani M, Rahman M, Rai RK, Ram U, Reitsma MB, Renzaho AMN, Rios-Blancas MJ, Safiri S, Salomon JA, Sartorius B, Sepanlou SG, Shaikh MA, Silva D, Stranges S, Tabarés-Seisdedos R, Atnafu NT, Thakur JS, Topor-Madry R, Truelsen T, Tuzcu EM, Tyrovolas S, Ukwaja KN, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Weintraub R, Wolfe C, Workicho A, Xu G, Yadgir S, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Zaidi Z, El Sayed Zaki M, Zipkin B, Afshin A, Gakidou E, Lim SS, Mokdad AH, Naghavi M, Vos T, Murray CJL. The Burden of cardiovascular diseases among US states, 1990-2016. JAMA Cardiology 2018 May;3(5):375-89.
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2016 Oct;37(39):2999-3058.
4. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet 2017 Jun;389(10088):2473-81.
5. Громова О.А., Ребров В.Г. Витамины, макро- и микроэлементы. Обучающие программы РСЦ института микроэлементов ЮНЕСКО. М.: Гэотар-Медиа; 2008. 954 с.
6. Громова О.А., Торшин И.Ю. Микронутриенты и репродуктивное здоровье. Руководство. М.: Геотар-Медиа; 2019. 672 c.
7. Ежов М.В., Катапано А., Эскобар К., Кухарчук В.В., Воевода М.И., Драпкина О.М., Шальнова С.А., Стародубова А.В., Гуревич В.С., Шапошник И.И., Большакова О.О., Ойноткинова О.Ш., Алиева А.С. Роль препаратов на основе красного дрожжевого риса в немедикаментозной коррекции дислипидемии при низком и умеренном сердечнососудистом риске (заключение экспертов). Рациональная Фармакотерапия в Кардиологии 2020;16(1):147-55.
8. Steffen C. Rotschimmelreis: ein bedenkliches Nahrungsergänzungsmittel? [Red yeast rice: an unsafe food supplement?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017 Mar;60(3):292-6.
9. Gong ES, Liu C, Li B, Zhou W, Chen H, Li T, Wu J, Zeng Z, Wang Y, Si X, Lang Y, Zhang Y, Zhang W, Zhang G, Luo S, Liu RH. Phytochemical profiles of rice and their cellular antioxidant activity against ABA induced oxidative stress in human hepatocellular carcinoma HepG2 cells. Food Chemistry 2020 Jul;318:126484.
10. Jun HI, Song GS, Yang EI, Youn Y, Kim YS. Antioxidant activities and phenolic compounds of pigmented rice bran extracts. Journal of Food Sciences 2012 Jul;77(7):C759-64.
11. Sumczynski D, Kotásková E, Družbíková H, Mlček J. Determination of contents and antioxidant activity of free and bound phenolics compounds and in vitro digestibility of commercial black and red rice (Oryza sativa L.) varieties. Food Chemistry 2016 Nov;211:339-46.
12. Feng Y, Xu H, Chen K. Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. Journal of Alternative and Complementary Medicine (New York, N.Y.) 2012 Apr;18(4):318-28.
13. Li XM, Shen XH, Duan ZW, Guo SR. A new monacolin analogue from Xuezhikang capsule. Yao Xue Xue Bao 2011 May;46(5):564-7.
14. Klingelhöfer I, Morlock GE. Lovastatin in lactone and hydroxy acid forms and citrinin in red yeast rice powders analyzed by HPTLC-UV/FLD. Analytical and Bioanalytical Chemistry 2019 Oct;411(25):6655-65.
15. Del Gaudio F, Guerrera IC, Riccio R, Monti MC. Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes. Molecular Omics 2020 Feb;16(1):19-30.
16. Feng D, Sun JG, Sun RB, Ou-Yang BC, Yao L, Aa JY, Zhou F, Zhang JW, Zhang J, Wang GJ. Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice. Acta Pharmacologica Sinica 2015 Dec;36(12):1462-72.
17. Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. International Journal of Pharmaceutics 2013 Feb;444(1-2):18-24.
18. Feng D, Ge C, Tan ZY, Sun JG, Xie Y, Yao L, Yan CX, Aa JY, Wang GJ. Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Acta Pharmacologica Sinica 2018 Nov;39(11):1804-15.
19. Li C, Su C, Wang Y, Gao Y, Wang H, Tian J, Fu F. A 26-week toxicological study of Xuezhikang (XZK), red yeast rice extract, in beagle dogs with a 4-week recovery period. Regulatory Toxicology and Pharmacology 2020 Nov;117:104781.
20. Gao Y, Chen X, Li C, Wang H, Tian J, Fu F. Toxicological evaluation of, red rice yeast extract, Xuezhikang: acute, 26-week chronic and genotoxicity studies. Regulatory Toxicology and Pharmacology 2020 Jul;114:104654.
21. Limtrakul P, Yodkeeree S, Punfa W, Srisomboon J. Inhibition of the MAPK signaling pathway by red rice extract in UVB-irradiated human skin fibroblasts. Natural Products Communications 2016 Dec;11(12):1877-82.
22. Limtrakul P, Yodkeeree S, Pitchakarn P, Punfa W. Anti-inflammatory effects of proanthocyanidin-rich red rice extract via suppression of MAPK, AP-1 and NF-κB pathways in RAW 264.7 macrophages. Nutrition Research & Practice 2016 Jun;10(3):251-8.
23. Sinthorn W, Chatuphonprasert W, Chulasiri M, Jarukamjorn K. Thai red rice extract provides liver protection in paracetamol-treated mice by restoring the glutathione system. Pharmatheutical Biology 2016;54(5):770-9.
24. Chu S, Hu L, Wang X, Sun S, Zhang T, Sun Z, Shen L, Jin S, He B. Xuezhikang ameliorates contrast media-induced nephropathy in rats via suppression of oxidative stress, inflammatory responses and apoptosis. Renal Failure 2016 Nov;38(10):1717-25.
25. Liang L, Shao W, Shu T, Zhang Y, Xu S, Guo L, Zhou Y, Huang H, Sun P. Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway. Biomedicine & Pharmacotherapy 2019 Jun;114:108817.
26. Ding M, Si D, Zhang W, Feng Z, He M, Yang P. Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia. Experimental and Therapeutic Medicine 2014 Dec;8(6):1737-44.
27. Fan XF, Deng YQ, Ye L, Li YD, Chen J, Lu WW, Li JP. Effect of Xuezhikang capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chinese Journal of Integrative Medicine 2010 Apr;16(2):119-23.
28. Callcott ET, Blanchard CL, Snell P, Santhakumar AB. The anti-inflammatory and antioxidant effects of pigmented rice consumption in an obese cohort. Food & Function 2019 Dec;10(12):8016-25.
29. Callcott ET, Blanchard CL, Snell P, Santhakumar AB. The anti-inflammatory and antioxidant effects of acute consumption of pigmented rice in humans. Food & Function 2019 Dec;10(12):8230-9.
30. Li P, Yang Y, Liu M. Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation. Journal of Cardiovascular Pharmacology 2011 Sep;58(3):307-18.
31. Lu WN, Zheng FP, Lai DW, Li H. Xuezhikang (XZK) reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family. Chinese Journal of Integrative Medicine 2016 Aug;22(8):611-8.
32. Lin CM, Lin YT, Lin RD, Huang WJ, Lee MH. Neurocytoprotective effects of aliphatic hydroxamates from lovastatin, a secondary metabolite from monascus-fermented red mold rice, in 6-hydroxydopamine (6-OHDA)-treated nerve growth factor (NGF)-differentiated PC12 cells. ACS Chemical Neuroscience 2015 May;6(5):716-24.
33. Shen L, Sun Z, Chu S, Cai Z, Nie P, Wu C, Yuan R, Hu L, He B. Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation. PLoS One 2017 Nov;12(11):e0188841.
34. Chung NJ, Choi KC, Lee SA, Baek JA, Lee JC. Rice hull extracts inhibit proliferation of MCF-7 cells with G1 cell cycle arrest in parallel with their antioxidant activity. Journal of Medicinal Food 2015 Mar;18(3):314-23.
35. Subkamkaew C, Limtrakul Dejkriengkraikul P, Yodkeeree S. Proanthocyanidin-rich fractions from red rice extract enhance TNF-α-induced cell death and suppress invasion of human lung adenocarcinoma cell A549. Molecules (Basel, Switzerland) 2019 Sep;24(18):3393.
36. Boue SM, Daigle KW, Chen MH, Cao H, Heiman ML. Antidiabetic potential of purple and red rice (Oryza sativa L.) bran extracts. Journal of Agricultural and Food Chemistry 2016 Jul;64(26):5345-53.
37. Krishnan V, Rani R, Awana M, Pitale D, Kulshreshta A, Sharma S, Bollinedi H, Singh A, Singh B, Singh AK, Praveen S. Role of nutraceutical starch and proanthocyanidins of pigmented rice in regulating hyperglycemia: enzyme inhibition, enhanced glucose uptake and hepatic glucose homeostasis using in vitro model. Food Chemistry 2021 Jan;335:127505.
38. Wang J, Jiang W, Zhong Y, Lu B, Shao J, Jiang S, Gu P. Xuezhikang attenuated the functional and morphological impairment of pancreatic islets in diabetic mice via the inhibition of oxidative stress. Journal of Cardiovascular Pharmacology 2014 Mar;63(3):282-9.
39. Park Y, Park EM, Kim EH, Chung IM. Hypocholesterolemic metabolism of dietary red pericarp glutinous rice rich in phenolic compounds in mice fed a high cholesterol diet. Nutrition Research and Practice 2014 Dec;8(6):632-7.
40. Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway. PLoS One 2017 Sep;12(9):e0184949.
41. Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, Ye P. Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels. Disease Markers 2014;2014:781780.
42. Stefanutti C, Mazza F, Mesce D, Morozzi C, Di Giacomo S, Vitale M, Pergolini M. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: a clinical study. Atherosclerosis Supplements 2017 Nov;30:86-91.
43. Xu RX, Zhang Y, Guo YL, Ma CY, Yao YH, Li S, Li XL, Qing P, Gao Y, Wu NQ, Zhu CG, Liu G, Dong Q, Sun J, Li JJ. Novel findings in relation to multiple anti-atherosclerotic effects of Xuezhikang in humans. Chronic Diseases and Translational Medicine 2017 Nov;4(2):117-26.
44. Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. Journal of Clinical Lipidology 2014 Nov-Dec;8(6):568-75.
45. Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clinical Chemistry 2003 Aug;49(8):1347-52.
46. Jian J, Hao X, Deng C, Zhou H, Lin J. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. Zhonghua Nei Ke Za Zhi 1999 Aug;38(8):517-9.
47. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics 2016 Apr;41(2):170-9.
48. Li M, He Q, Chen Y, Li B, Feng B, Zhang Z, Wang J. Xuezhikang capsule for type 2 diabetes with hyperlipemia: a systematic review and meta-analysis of randomized clinical trails. Evidence-Based Complementary and Alternative Medicine 2015;2015:468520.
49. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014 Jun;9(6):e98611.
50. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 2006 Nov;1:4.
51. Lin ZW, Wang Z, Zhu GP, Li BW, Xie WL, Xiang DC. Hypertensive vascular remodeling was inhibited by Xuezhikang through the regulation of fibulin-3 and MMPs in spontaneously hypertensive rats. International Journal of Clinical and Experimental Medicine 2015 Feb;8(2):2118-27.
52. Zheng J, Xiao T, Ye P, Miao D, Wu H. Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study. Brazilian Journal of Medical and Biological Research 2017 Aug;50(10):e6363.
53. Gong C, Huang SL, Huang JF, Zhang ZF, Luo M, Zhao Y, Jiang XJ. Effects of combined therapy of Xuezhikang capsule and valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence. Chinese Journal of Integrative Medicine 2010 Apr;16(2):114-8.
54. Liu ZQ, Cui LQ, Wang Y. [Effect of Xuezhikang on cardiac function, serum C-reactive protein and blood lipid in patients with chronic heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007 Mar;27(3):220-2.
55. MacKay D, Hathcock J, Guarneri E. Niacin: chemical forms, bioavailability, and health effects. Nutrition Reviews 2012 Jun;70(6):357-66.
56. Suárez-Rivero JM, Pastor-Maldonado CJ, de la Mata M, Villanueva-Paz M, Povea- Cabello S, Álvarez-Córdoba M, Villalón-García I, Suárez-Carrillo A, Talaverón-Rey M, Munuera M, Sánchez-Alcázar JA. Atherosclerosis and coenzyme Q10. International Journal of Molecular Sciences 2019 Oct;20(20):5195.
57. Plaza-Díaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 2017 May;9(6):555.
58. Grill JP, Crociani J, Ballongue J. Effect of bifidobacteria on nitrites and nitrosamines. Letters in Applied Microbiology 1995 May;20(5):328-30.

References

1. Kukharchuk VV. About new version of recommendations for correction of dyslipidemia to prevent atherosclerosis and its complications. The Journal of Atherosclerosis and Dyslipidaemias 2020;1(38):5-6 (In Russian).
2. Global Burden of Cardiovascular Diseases Collaboration; Roth GA, Johnson CO, Abate KH, Abd-Allah F, Ahmed M, Alam K, Alam T, Alvis-Guzman N, Ansari H, Ärnlöv J, Atey TM, Awasthi A, Awoke T, Barac A, Bärnighausen T, Bedi N, Bennett D, Bensenor I, Biadgilign S, Castañeda-Orjuela C, Catalá-López F, Davletov K, Dharmaratne S, Ding EL, Dubey M, Aquino Faraon EJ, Farid T, Farvid MS, Feigin V, Fernandes J, Frostad J, Gebru A, Geleijnse JM, Gona PN, Griswold M, Hailu GB, Hankey GJ, Hassen HY, Havmoeller R, Hay S, Heckbert SR, Irvine CMS, James SL, Jara D, Kasaeian A, Khan AR, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Lal D, Larsson A, Linn S, Lotufo PA, Abd El Razek NM, Mazidi M, Meier T, Mendoza W, Mensah GA, Meretoja A, Mezgebe HB, Mirrakhimov E, Mohammed S, Moran AE, Nguyen G, Nguyen M, Ong KL, Owolabi M, Pletcher M, Pourmalek F, Purcell CA, Qorbani M, Rahman M, Rai RK, Ram U, Reitsma MB, Renzaho AMN, Rios-Blancas MJ, Safiri S, Salomon JA, Sartorius B, Sepanlou SG, Shaikh MA, Silva D, Stranges S, Tabarés-Seisdedos R, Atnafu NT, Thakur JS, Topor-Madry R, Truelsen T, Tuzcu EM, Tyrovolas S, Ukwaja KN, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Weintraub R, Wolfe C, Workicho A, Xu G, Yadgir S, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Zaidi Z, El Sayed Zaki M, Zipkin B, Afshin A, Gakidou E, Lim SS, Mokdad AH, Naghavi M, Vos T, Murray CJL. The Burden of cardiovascular diseases among US states, 1990-2016. JAMA Cardiology 2018 May;3(5):375-89.
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. European Heart Journal 2016 Oct;37(39):2999-3058.
4. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet 2017 Jun;389(10088):2473-81.
5. Gromova OA, Rebrov VG. Vitamins, macro- and microelements. RSC training programs of Trace Element-Institute for UNESCO. Moscow: Geotar-Media; 2008. 954 p. (In Russian).
6. Gromova OA, Torshin IYu. Micronutrients and reproductive health: manual. Moscow: Geotar-Media; 2019. 672 p. (In Russian).
7. Yezhov MV, Catapano A, Escobar K, Kukharchuk VV, Voyevoda MI, Drapkina OM, Shalnova SA, Starodubova AV, Gurevich VS, Shaposhnik II, Bolshakova OO, Oynotkinova OS, Aliyeva AS. Red yeast rice based medications in nonpharmacological correction of dyslipidemia in low and moderate cardiovascular risk: Expert opinion. Rational Pharmacotherapy in Cardiology 2020;16(1):147-55 (In Russian).
8. Steffen C. Rotschimmelreis: ein bedenkliches Nahrungsergänzungsmittel? [Red yeast rice: an unsafe food supplement?]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017 Mar;60(3):292-6.
9. Gong ES, Liu C, Li B, Zhou W, Chen H, Li T, Wu J, Zeng Z, Wang Y, Si X, Lang Y, Zhang Y, Zhang W, Zhang G, Luo S, Liu RH. Phytochemical profiles of rice and their cellular antioxidant activity against ABA induced oxidative stress in human hepatocellular carcinoma HepG2 cells. Food Chemistry 2020 Jul;318:126484.
10. Jun HI, Song GS, Yang EI, Youn Y, Kim YS. Antioxidant activities and phenolic compounds of pigmented rice bran extracts. Journal of Food Sciences 2012 Jul;77(7):C759-64.
11. Sumczynski D, Kotásková E, Družbíková H, Mlček J. Determination of contents and antioxidant activity of free and bound phenolics compounds and in vitro digestibility of commercial black and red rice (Oryza sativa L.) varieties. Food Chemistry 2016 Nov;211:339-46.
12. Feng Y, Xu H, Chen K. Natural polypill Xuezhikang: its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. Journal of Alternative and Complementary Medicine (New York, N.Y.) 2012 Apr;18(4):318-28.
13. Li XM, Shen XH, Duan ZW, Guo SR. A new monacolin analogue from Xuezhikang capsule. Yao Xue Xue Bao 2011 May;46(5):564-7.
14. Klingelhöfer I, Morlock GE. Lovastatin in lactone and hydroxy acid forms and citrinin in red yeast rice powders analyzed by HPTLC-UV/FLD. Analytical and Bioanalytical Chemistry 2019 Oct;411(25):6655-65.
15. Del Gaudio F, Guerrera IC, Riccio R, Monti MC. Quantitative proteomics discloses monacolin K-induced alterations in triple-negative breast cancer cell proteomes and phosphoproteomes. Molecular Omics 2020 Feb;16(1):19-30.
16. Feng D, Sun JG, Sun RB, Ou-Yang BC, Yao L, Aa JY, Zhou F, Zhang JW, Zhang J, Wang GJ. Isoflavones and phytosterols contained in Xuezhikang capsules modulate cholesterol homeostasis in high-fat diet mice. Acta Pharmacologica Sinica 2015 Dec;36(12):1462-72.
17. Chen CH, Yang JC, Uang YS, Lin CJ. Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products. International Journal of Pharmaceutics 2013 Feb;444(1-2):18-24.
18. Feng D, Ge C, Tan ZY, Sun JG, Xie Y, Yao L, Yan CX, Aa JY, Wang GJ. Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Acta Pharmacologica Sinica 2018 Nov;39(11):1804-15.
19. Li C, Su C, Wang Y, Gao Y, Wang H, Tian J, Fu F. A 26-week toxicological study of Xuezhikang (XZK), red yeast rice extract, in beagle dogs with a 4-week recovery period. Regulatory Toxicology and Pharmacology 2020 Nov;117:104781.
20. Gao Y, Chen X, Li C, Wang H, Tian J, Fu F. Toxicological evaluation of, red rice yeast extract, Xuezhikang: acute, 26-week chronic and genotoxicity studies. Regulatory Toxicology and Pharmacology 2020 Jul;114:104654.
21. Limtrakul P, Yodkeeree S, Punfa W, Srisomboon J. Inhibition of the MAPK signaling pathway by red rice extract in UVB-irradiated human skin fibroblasts. Natural Products Communications 2016 Dec;11(12):1877-82.
22. Limtrakul P, Yodkeeree S, Pitchakarn P, Punfa W. Anti-inflammatory effects of proanthocyanidin-rich red rice extract via suppression of MAPK, AP-1 and NF-κB pathways in RAW 264.7 macrophages. Nutrition Research & Practice 2016 Jun;10(3):251-8.
23. Sinthorn W, Chatuphonprasert W, Chulasiri M, Jarukamjorn K. Thai red rice extract provides liver protection in paracetamol-treated mice by restoring the glutathione system. Pharmatheutical Biology 2016;54(5):770-9.
24. Chu S, Hu L, Wang X, Sun S, Zhang T, Sun Z, Shen L, Jin S, He B. Xuezhikang ameliorates contrast media-induced nephropathy in rats via suppression of oxidative stress, inflammatory responses and apoptosis. Renal Failure 2016 Nov;38(10):1717-25.
25. Liang L, Shao W, Shu T, Zhang Y, Xu S, Guo L, Zhou Y, Huang H, Sun P. Xuezhikang improves the outcomes of cardiopulmonary resuscitation in rats by suppressing the inflammation response through TLR4/NF-κB pathway. Biomedicine & Pharmacotherapy 2019 Jun;114:108817.
26. Ding M, Si D, Zhang W, Feng Z, He M, Yang P. Red yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia. Experimental and Therapeutic Medicine 2014 Dec;8(6):1737-44.
27. Fan XF, Deng YQ, Ye L, Li YD, Chen J, Lu WW, Li JP. Effect of Xuezhikang capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia. Chinese Journal of Integrative Medicine 2010 Apr;16(2):119-23.
28. Callcott ET, Blanchard CL, Snell P, Santhakumar AB. The anti-inflammatory and antioxidant effects of pigmented rice consumption in an obese cohort. Food & Function 2019 Dec;10(12):8016-25.
29. Callcott ET, Blanchard CL, Snell P, Santhakumar AB. The anti-inflammatory and antioxidant effects of acute consumption of pigmented rice in humans. Food & Function 2019 Dec;10(12):8230-9.
30. Li P, Yang Y, Liu M. Xuezhikang, extract of red yeast rice, inhibited tissue factor and hypercoagulable state through suppressing nicotinamide adenine dinucleotide phosphate oxidase and extracellular signal-regulated kinase activation. Journal of Cardiovascular Pharmacology 2011 Sep;58(3):307-18.
31. Lu WN, Zheng FP, Lai DW, Li H. Xuezhikang (XZK) reduced renal cell apoptosis in streptozocin-induced diabetic rats through regulation of Bcl-2 family. Chinese Journal of Integrative Medicine 2016 Aug;22(8):611-8.
32. Lin CM, Lin YT, Lin RD, Huang WJ, Lee MH. Neurocytoprotective effects of aliphatic hydroxamates from lovastatin, a secondary metabolite from monascus-fermented red mold rice, in 6-hydroxydopamine (6-OHDA)-treated nerve growth factor (NGF)-differentiated PC12 cells. ACS Chemical Neuroscience 2015 May;6(5):716-24.
33. Shen L, Sun Z, Chu S, Cai Z, Nie P, Wu C, Yuan R, Hu L, He B. Xuezhikang, an extract from red yeast rice, attenuates vulnerable plaque progression by suppressing endoplasmic reticulum stress-mediated apoptosis and inflammation. PLoS One 2017 Nov;12(11):e0188841.
34. Chung NJ, Choi KC, Lee SA, Baek JA, Lee JC. Rice hull extracts inhibit proliferation of MCF-7 cells with G1 cell cycle arrest in parallel with their antioxidant activity. Journal of Medicinal Food 2015 Mar;18(3):314-23.
35. Subkamkaew C, Limtrakul Dejkriengkraikul P, Yodkeeree S. Proanthocyanidin-rich fractions from red rice extract enhance TNF-α-induced cell death and suppress invasion of human lung adenocarcinoma cell A549. Molecules (Basel, Switzerland) 2019 Sep;24(18):3393.
36. Boue SM, Daigle KW, Chen MH, Cao H, Heiman ML. Antidiabetic potential of purple and red rice (Oryza sativa L.) bran extracts. Journal of Agricultural and Food Chemistry 2016 Jul;64(26):5345-53.
37. Krishnan V, Rani R, Awana M, Pitale D, Kulshreshta A, Sharma S, Bollinedi H, Singh A, Singh B, Singh AK, Praveen S. Role of nutraceutical starch and proanthocyanidins of pigmented rice in regulating hyperglycemia: enzyme inhibition, enhanced glucose uptake and hepatic glucose homeostasis using in vitro model. Food Chemistry 2021 Jan;335:127505.
38. Wang J, Jiang W, Zhong Y, Lu B, Shao J, Jiang S, Gu P. Xuezhikang attenuated the functional and morphological impairment of pancreatic islets in diabetic mice via the inhibition of oxidative stress. Journal of Cardiovascular Pharmacology 2014 Mar;63(3):282-9.
39. Park Y, Park EM, Kim EH, Chung IM. Hypocholesterolemic metabolism of dietary red pericarp glutinous rice rich in phenolic compounds in mice fed a high cholesterol diet. Nutrition Research and Practice 2014 Dec;8(6):632-7.
40. Zhao SP, Li R, Dai W, Yu BL, Chen LZ, Huang XS. Xuezhikang contributes to greater triglyceride reduction than simvastatin in hypertriglyceridemia rats by up-regulating apolipoprotein A5 via the PPARα signaling pathway. PLoS One 2017 Sep;12(9):e0184949.
41. Cao R, Bai Y, Sun L, Zheng J, Zu M, Du G, Ye P. Xuezhikang therapy increases miR-33 expression in patients with low HDL-C levels. Disease Markers 2014;2014:781780.
42. Stefanutti C, Mazza F, Mesce D, Morozzi C, Di Giacomo S, Vitale M, Pergolini M. Monascus purpureus for statin and ezetimibe intolerant heterozygous familial hypercholesterolaemia patients: a clinical study. Atherosclerosis Supplements 2017 Nov;30:86-91.
43. Xu RX, Zhang Y, Guo YL, Ma CY, Yao YH, Li S, Li XL, Qing P, Gao Y, Wu NQ, Zhu CG, Liu G, Dong Q, Sun J, Li JJ. Novel findings in relation to multiple anti-atherosclerotic effects of Xuezhikang in humans. Chronic Diseases and Translational Medicine 2017 Nov;4(2):117-26.
44. Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study. Journal of Clinical Lipidology 2014 Nov-Dec;8(6):568-75.
45. Liu L, Zhao SP, Cheng YC, Li YL. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clinical Chemistry 2003 Aug;49(8):1347-52.
46. Jian J, Hao X, Deng C, Zhou H, Lin J. [The effects of Xuezhikang on serum lipid profile, thromboxane A2 and prostacyclin in patients with hyperlipidemia]. Zhonghua Nei Ke Za Zhi 1999 Aug;38(8):517-9.
47. Ong YC, Aziz Z. Systematic review of red yeast rice compared with simvastatin in dyslipidaemia. Journal of Clinical Pharmacy and Therapeutics 2016 Apr;41(2):170-9.
48. Li M, He Q, Chen Y, Li B, Feng B, Zhang Z, Wang J. Xuezhikang capsule for type 2 diabetes with hyperlipemia: a systematic review and meta-analysis of randomized clinical trails. Evidence-Based Complementary and Alternative Medicine 2015;2015:468520.
49. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014 Jun;9(6):e98611.
50. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fønnebø V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chinese Medicine 2006 Nov;1:4.
51. Lin ZW, Wang Z, Zhu GP, Li BW, Xie WL, Xiang DC. Hypertensive vascular remodeling was inhibited by Xuezhikang through the regulation of fibulin-3 and MMPs in spontaneously hypertensive rats. International Journal of Clinical and Experimental Medicine 2015 Feb;8(2):2118-27.
52. Zheng J, Xiao T, Ye P, Miao D, Wu H. Xuezhikang reduced arterial stiffness in patients with essential hypertension: a preliminary study. Brazilian Journal of Medical and Biological Research 2017 Aug;50(10):e6363.
53. Gong C, Huang SL, Huang JF, Zhang ZF, Luo M, Zhao Y, Jiang XJ. Effects of combined therapy of Xuezhikang capsule and valsartan on hypertensive left ventricular hypertrophy and heart rate turbulence. Chinese Journal of Integrative Medicine 2010 Apr;16(2):114-8.
54. Liu ZQ, Cui LQ, Wang Y. [Effect of Xuezhikang on cardiac function, serum C-reactive protein and blood lipid in patients with chronic heart failure]. Zhongguo Zhong Xi Yi Jie He Za Zhi 2007 Mar;27(3):220-2.
55. MacKay D, Hathcock J, Guarneri E. Niacin: chemical forms, bioavailability, and health effects. Nutrition Reviews 2012 Jun;70(6):357-66.
56. Suárez-Rivero JM, Pastor-Maldonado CJ, de la Mata M, Villanueva-Paz M, Povea- Cabello S, Álvarez-Córdoba M, Villalón-García I, Suárez-Carrillo A, Talaverón-Rey M, Munuera M, Sánchez-Alcázar JA. Atherosclerosis and coenzyme Q10. International Journal of Molecular Sciences 2019 Oct;20(20):5195.
57. Plaza-Díaz J, Ruiz-Ojeda FJ, Vilchez-Padial LM, Gil A. Evidence of the anti-inflammatory effects of probiotics and synbiotics in intestinal chronic diseases. Nutrients 2017 May;9(6):555.
58. Grill JP, Crociani J, Ballongue J. Effect of bifidobacteria on nitrites and nitrosamines. Letters in Applied Microbiology 1995 May;20(5):328-30.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]